Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
2023-05-04 04:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 3.75% (Institutional Shares) during the first q...
2023-04-25 02:01:13 ET Summary To identify the most promising pharmaceutical companies with a market capitalization of more than $1 billion, we use an eight-step selection process, which will be discussed below. The following two articles will feature our list of the top 10 pharma...
Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under i...
Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab...
Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18 , 2...
Media Release COPENHAGEN, Denmark; April 1 7 , 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Disc...
Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Ch...
Company Announcement Repurchase of up to 2 2 0,000 shares H onoring commitments under our Restricted Stock Unit program Completion expected on March 31 , 2023 COPENHAGEN , Denmark; February 22, 20 2 3 ...
Company Announcement COPENHAGEN , Denmark; February 22, 2023 – Genmab A/S ( Nasdaq: GMAB ) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year an...
Company Announcement Net sales of DARZALEX ® in 2022 totaled USD 7, 977 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc . (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...